Ronald Feld
#158,992
Most Influential Person Now
Ronald Feld's AcademicInfluence.com Rankings
Ronald Feldmedical Degrees
Medical
#3163
World Rank
#3618
Historical Rank
Oncology
#219
World Rank
#227
Historical Rank
Ronald Feldphilosophy Degrees
Philosophy
#9097
World Rank
#12603
Historical Rank
Logic
#6088
World Rank
#7570
Historical Rank
Download Badge
Medical Philosophy
Ronald Feld's Degrees
- Doctorate Medicine University of Medicine, Taunggyi
- PhD Oncology University of Health Sciences
Why Is Ronald Feld Influential?
(Suggest an Edit or Addition)Ronald Feld's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. (2002) (1845)
- The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. (2000) (1023)
- Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. (1988) (728)
- 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. (1997) (608)
- Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained Fever—Reply (1991) (391)
- From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. (1990) (365)
- Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. (2005) (351)
- Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. (1989) (346)
- Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. (2015) (322)
- Sites of recurrence in resected stage I non-small-cell lung cancer: a guide for future studies. (1984) (307)
- Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. (2005) (289)
- VP-16 and cisplatin as first-line therapy for small-cell lung cancer. (1985) (278)
- Prognostic factors in patients with resected stage I non‐small cell lung cancer. A report from the Lung Cancer Study Group (1984) (265)
- From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. (1990) (261)
- Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. (2007) (244)
- Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. (2009) (234)
- First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. (2012) (233)
- Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. (1987) (218)
- Ceftazidime Compared with Piperacillin and Tobramycin for the Empiric Treatment of Fever in Neutropenic Patients with Cancer: A Multicenter Randomized Trial (1994) (216)
- Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. (1997) (182)
- A randomized study of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small-cell lung cancer. (1987) (178)
- Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer. (1985) (177)
- Mycobacteriosis in patients with malignant disease. (1976) (173)
- Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer. (2014) (170)
- Surgical treatment for limited small-cell lung cancer. The University of Toronto Lung Oncology Group experience. (1991) (145)
- Influence of age on the treatment of limited-stage small-cell lung cancer. (1996) (143)
- Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC). (2017) (129)
- Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. (1987) (129)
- Limited impact of total parenteral nutrition on nutritional status during treatment for small cell lung cancer. (1985) (129)
- Differential expression of matrix metalloproteinases and their inhibitors in non‐small cell lung cancer (2000) (128)
- Factors associated with bacteraemia in febrile, granulocytopenic cancer patients. The International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). (2008) (127)
- A prospective study of adjuvant surgical resection after chemotherapy for limited small cell lung cancer. A University of Toronto Lung Oncology Group study. (1989) (126)
- Varicella-zoster infection in adult cancer patients. A population study. (1988) (121)
- Adjuvant chemotherapy following surgical resection for small-cell carcinoma of the lung. (1988) (120)
- Intracranial recurrence of carcinoma after complete surgical resection of stage I, II, and III non-small-cell lung cancer. (1988) (118)
- Hepatic candidiasis: an increasing problem in immunocompromised patients. (1987) (117)
- A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy: The “SMART” Approach for Resectable Malignant Pleural Mesothelioma (2014) (116)
- Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases. (2006) (112)
- Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. (2003) (110)
- Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung. (1984) (109)
- Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma. (2016) (109)
- Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. (2000) (107)
- Influence of sex on toxicity and treatment outcome in small-cell lung cancer. (2005) (105)
- Complications associated with Ommaya reservoirs in patients with cancer. The Princess Margaret Hospital experience and a review of the literature. (1990) (104)
- Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study. (2012) (104)
- Uncommon EGFR mutations in advanced non-small cell lung cancer. (2017) (103)
- Changes in body composition in patients with small-cell lung cancer. The effect of total parenteral nutrition as an adjunct to chemotherapy. (1984) (101)
- Supporting treatment decision making in advanced cancer: a randomized trial of a decision aid for patients with advanced colorectal cancer considering chemotherapy. (2011) (99)
- Bloodstream infections in cancer patients with febrile neutropenia. (2008) (97)
- Ectopic corticotropin syndrome and small-cell carcinoma of the lung. Clinical features, outcome, and complications. (1993) (96)
- The influence of age on the delivery, tolerance, and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. (1999) (96)
- Late neurological complications after prophylactic cranial irradiation in patients with small-cell lung cancer: the Toronto experience. (1990) (94)
- Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma. (2010) (94)
- Neurologic disorders in patients with small cell lung cancer (1987) (90)
- Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD‐1 Axis Inhibitors in Patients With Advanced Non–Small‐Cell Lung Cancer (2018) (88)
- Is there ever a role for salvage operations in limited small-cell lung cancer? (1991) (86)
- Reduction in local recurrence and improved survival in surgically treated patients with small cell lung cancer. (1983) (85)
- Cost-effectiveness of cancer chemotherapy: an economic evaluation of a randomized trial in small-cell lung cancer. (1988) (85)
- The effect of dose of thoracic irradiation on recurrence in patients with limited stage small cell lung cancer. Initial results of a Canadian Multicenter Randomized Trial. (1988) (85)
- The prognostic significance of pretreatment serum lactate dehydrogenase in patients with small-cell lung cancer. (1991) (83)
- Causes of death in patients with malignant lymphoma (1974) (83)
- Superior vena caval obstruction syndrome in small cell lung cancer (1986) (82)
- Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer. (1987) (81)
- Effects of total parenteral nutrition and chemotherapy on the metabolic derangements in small cell lung cancer. (1984) (80)
- Importance of clinical staging in limited small-cell lung cancer: a valuable system to separate prognostic subgroups. The University of Toronto Lung Oncology Group. (1993) (79)
- Does the incidence and outcome of brain metastases in locally advanced non-small cell lung cancer justify prophylactic cranial irradiation or early detection? (2005) (77)
- Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer. (2002) (76)
- Phase II study of activated charcoal to prevent irinotecan-induced diarrhea. (2004) (75)
- ALK‐Rearranged Non–Small‐Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism (2017) (72)
- Adjuvant Chemotherapy for Early-Stage Non-small Cell Lung Cancer. (2005) (71)
- VP‐16 alone and in combination with cisplatin in previously treated patients with small cell lung cancer (1984) (70)
- Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic review. (2015) (69)
- Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer. (1997) (68)
- Vancomycin as part of initial empirical antibiotic therapy for febrile neutropenia in patients with cancer: pros and cons. (1999) (65)
- Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group (2011) (65)
- Carcinoembryonic antigen: a useful prognostic marker in small-cell lung cancer. (1985) (65)
- Quinolone-Based Antibacterial Chemoprophylaxis in Neutropenic Patients: Effect of Augmented Gram-Positive Activity on Infectious Morbidity (1996) (64)
- Methodology for clinical trials involving patients with cancer who have febrile neutropenia: updated guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies. (2002) (63)
- Chemotherapy-Induced Oral Mucositis (2000) (63)
- Amikacin therapy of infections in neutropenic patients (1975) (62)
- Effect of adjuvant central iv hyperalimentation on the survival and response to treatment of patients with small cell lung cancer: a randomized trial. (1985) (61)
- Combined modality treatment of small cell carcinoma of the lung. (1981) (61)
- Infections in patients with malignant lymphoma treated with combination chemotherapy (1977) (58)
- Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial (2002) (58)
- Is bone marrow examination in small-cell lung cancer really necessary? (1986) (55)
- International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small cell lung cancer (aNSCLC): The TORCH trial. (2010) (54)
- Evolution of Symptom Burden of Advanced Lung Cancer Over a Decade (2017) (53)
- Metallothionein expression in patients with small cell carcinoma of the lung (2001) (53)
- Transarterial chemoembolisation for advanced hepatocellular carcinoma: results from a North American cancer centre. (2006) (53)
- Once-daily therapy with ceftriaxone compared with daily multiple-dose therapy with cefotaxime for serious bacterial infections: a randomized, double-blind study. (1989) (53)
- A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168) (2008) (53)
- Does Intensive Follow-up Alter Outcome in Patients with Advanced Lung Cancer? (2007) (53)
- Treatment of the Elderly When Cure is the Goal: The Influence of Age on Treatment Selection and Efficacy for Stage III Non-small Cell Lung Cancer (2011) (53)
- Patients with Advanced Non–Small Cell Lung Cancer: Are Research Biopsies a Barrier to Participation in Clinical Trials? (2016) (52)
- β-Lactum antibiotics alone or in combination with gentamicin for therapy of gram-negative bacillary infections in neutropenic patients (1976) (52)
- Pharmacology of Amikacin in Humans (1974) (52)
- Derivation of Utility Values from European Organization for Research and Treatment of Cancer Quality of Life-Core 30 Questionnaire Values in Lung Cancer (2010) (49)
- Randomized, double-blind, multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients. (2001) (49)
- First-line therapy with VP-16 and cisplatin for small-cell lung cancer. (1986) (47)
- Endpoints in cancer clinical trials: is there a need for measuring quality of life? (2004) (47)
- Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib and Erlotinib in the Treatment of Non-small Cell Lung Cancer: A Systematic Review (2006) (47)
- Intramedullary spinal cord metastases from small cell carcinoma of the lung. (1983) (46)
- Systemic infection by Rhodotorula spp. in the immunocompromised host. (1984) (45)
- Erratum: Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever (J. Infec. Dis. 1990; 161:381-396) (1990) (45)
- Early identification of neutropenic patients at risk of grampositive bacteraemia and the impact of empirical administration of vancomycin. (1996) (44)
- Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma (2016) (44)
- Pretreatment minimal staging and prognostic factors for non-small cell lung cancer. (1997) (43)
- Phase I-II study of high-dose epirubicin in advanced non-small-cell lung cancer. (1992) (42)
- Complications in the treatment of small cell carcinoma of the lung. (1981) (42)
- Prognostic factors in non-small cell lung cancer. (1991) (41)
- Referral Patterns for Adjuvant Chemotherapy in Patients with Completely Resected Non-small Cell Lung Cancer (2007) (41)
- Risk factors for varicella zoster disseminated infection among adult cancer patients with localized zoster (1988) (40)
- Enhancing treatment decision-making: pilot study of a treatment decision aid in stage IV non-small cell lung cancer (2008) (40)
- Superior vena cava obstruction syndrome: recommendations for management. (1985) (40)
- Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer. (2017) (38)
- VP-16 and carboplatin in previously untreated patients with extensive small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group. (1988) (37)
- Combination chemotherapy in invasive thymoma. Role of COPP (1980) (37)
- The use of VP-16 plus cisplatin during induction chemotherapy for small-cell lung cancer. (1986) (36)
- A multicenter comparative trial of tobramycin and ticarcillin vs moxalactam and ticarcillin in febrile neutropenic patients. (1985) (34)
- Cyclophosphamide, doxorubicin, and cisplatin in the treatment of non-small cell bronchogenic carcinoma. (1981) (34)
- Comparison of amikacin and tobramycin in the treatment of infection in patients with cancer. (1977) (34)
- A multicentre prospective randomized trial comparing ceftazidime with cefazolin/tobramycin in the treatment of hospitalized patients with non-pneumococcal pneumonia. (1983) (34)
- Amikacin for treatment of infections in patients with malignant diseases. (1976) (33)
- An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH tri (2008) (33)
- Empiric therapy for infections in patients with granulocytopenia. Continuous v interrupted infusion of tobramycin plus cefamandole. (1984) (32)
- Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: usefulness of mathematic modeling to determine maximum-tolerable dose. (1996) (32)
- Effects of intravenous hyperalimentation during treatment in patients with small-cell lung cancer. (1985) (31)
- Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma (2017) (30)
- Herpes zoster in patients with small-cell carcinoma of the lung receiving combined modality treatment. (1980) (28)
- Urticaria following intravenous doxorubicin administration. (1978) (28)
- The role of surveillance cultures in patients likely to develop chemotherapy-induced mucositis (1997) (28)
- A Phase II Study of PF‐03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207 (2016) (27)
- Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks. (1998) (26)
- Micrococcus luteus pneumonia: a case report and review of the literature. (1979) (25)
- Criteria for response in patients in clinical trials of empiric antibiotic regimens for febrile neutropenia. Is there agreement? (1998) (24)
- The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer. (2018) (23)
- IND.175: Phase I study of daily oral AZD2171, a vascular endothelial growth factor receptor inhibitor (VEGFRI), in combination with gemcitabine and cisplatin (G/C) in patients with advanced non-small cell lung cancer (ANSCLC): A study of the NCIC Clinical Trials Group (2007) (23)
- Herpes zoster in patients with carcinoma of the lung. (1982) (22)
- Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer (2012) (22)
- Experience with Ommaya Reservoir in 120 Consecutive Patients with Meningeal Malignancy (1990) (22)
- Current Perspectives and Future Directions in Palliative Medicine (1998) (22)
- Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma. (2014) (21)
- A preliminary report on the use of ceftizoxime vs. clindamycin/tobramycin for the therapy of intra-abdominal and pelvic infections. (1982) (21)
- Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy. (2015) (21)
- Gefitinib (IRESSA) with Vinorelbine or Vinorelbine/Cisplatin for Chemotherapy-Naive Non-small Cell Lung Cancer Patients (2006) (21)
- Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma (2016) (21)
- Changes in and Impact of the Death Review Process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. (2015) (20)
- Quality of life in patients with non-small cell lung cancer treated with chemotherapy. (1987) (20)
- A phase II study of Temozolomide in advanced untreated pancreatic cancer (2004) (19)
- Intravenous catheter infection study: a prospective trial in patients with neoplastic disease. (1975) (18)
- The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer: its prospective evaluation by a Multicenter Canadian Trial. (2002) (18)
- Short course prophylactic cranial irradiation for small cell lung cancer (1985) (17)
- Lung cancer in never smokers from the Princess Margaret Cancer Centre (2018) (17)
- A prospective randomized trial of ceftazidime versus cefazolin/tobramycin in the treatment of hospitalized patients with pneumonia. (1987) (16)
- Cefoperazone compared with ampicillin plus tobramycin for severe biliary tract infections (1988) (16)
- Empiric therapy for infections in granulocytopenic cancer patients: continuous infusion of amikacin plus cephalothin. (1979) (16)
- A phase I–II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798) (2008) (16)
- Impact of induction therapy on postoperative outcome after extrapleural pneumonectomy for malignant pleural mesothelioma: does induction-accelerated hemithoracic radiation increase the surgical risk? (2016) (15)
- A case of recurrent metastatic ameloblastoma and hypercalcaemia successfully treated with carboplatin and paclitaxel: long survival and prolonged stable disease (2013) (15)
- Radiofrequency ablation of malignant hepatic neoplasms. (2002) (15)
- Prognostic factors in patients with non-small cell lung cancer. A critique of the world literature (1991) (15)
- O-154 Impact of maintaining Hb with epoetin alfa on time toprogression (TTP), overall survival (OS), quality of life (QOL) and transfusion reduction in limited disease SCLC patients (2005) (15)
- The impact of anemia on outcome of chemoradiation for limited small-cell lung cancer: a combined analysis of studies of the National Cancer Institute of Canada Clinical Trials Group. (2007) (14)
- Chemotherapy as adjuvant therapy for completely resected non-small-cell lung cancer: have we made progress? (1996) (14)
- Chemotherapy-induced oral mucositis: new approaches to prevention and management (2005) (14)
- A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer (2013) (14)
- Small-cell lung cancer is still a problem. (1984) (13)
- Multinational cooperation in trials and guidelines dealing with febrile neutropenia. (2000) (12)
- A genetic sequence variant (GSV) at susceptibility loci of 5p15.33 (TERT-CLPTM1L) is associated with survival outcome in locally advanced and metastatic non-small-cell lung cancer (NSCLC). (2014) (12)
- Combination chemotherapy in invasive thymoma role of COPP. (1980) (12)
- The effect of intravenous hyperalimentation on the dietary intake of patients with small cell lung cancer. A randomized trial (1985) (11)
- Carcinoembryonic antigen, arginine vasopressin and calcitonin as markers of early small-cell lung cancer relapse. (1989) (10)
- Prognostic factors for small cell carcinoma of the lung. (1988) (10)
- Consensus report on combined radiotherapy and chemotherapy modalities in lung cancer. (1988) (10)
- 28 Results of a phase iii randomized controlled study comparing the survival of patients with unresectable hepatocellular carcinoma (HCC) treated with nolatrexed (NOL) or doxorubicin (DOX) (2006) (9)
- A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer (2012) (9)
- Systemic Therapy Use and Outcomes After Relapse from Preoperative Radiation and Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma. (2019) (9)
- Current perspectives in the treatment of non-small cell lung cancer (1993) (9)
- Differential expression of matrix metalloproteinases and their inhibitors in nonâsmall cell lung cancer (2000) (9)
- Phase II Study of Concurrent Pemetrexed, Cisplatin, and Radiation Therapy for Stage IIIA/B Unresectable Non-Small Cell Lung Cancer. (2016) (8)
- Capecitabine plus rofecoxib show no activity in patients with metastatic neuroendocrine tumours. (2006) (8)
- Septic arthritis due to saccharomyces species in a patient with chronic rheumatoid arthritis. (1982) (8)
- Upper half body irradiation (UHBI) for extensive small cell carcinoma of the lung. (1981) (8)
- Final results of the Canadian phase I dose escalation trial of gemcitabine and cisplatin for advanced non-small cell lung cancer. (1996) (8)
- The restaging of responding patients with limited small cell lung cancer. Is it really useful? (1993) (8)
- Staging and the evaluation of prognosis for patients with small-cell carcinoma of the lung. (1986) (7)
- Adjuvant chemoradiation for gastric cancer with infusional 5-fluorouracil and cisplatin: a phase I study. (2010) (7)
- Influence of gender on treatment outcome and toxicity in small cell lung cancer (SCLC). (2004) (6)
- The compromised host. (1989) (6)
- Fever associated with chemotherapy‐induced neutropenia: a review of current therapeutic approaches (1998) (6)
- Adjuvant sunitinib (Su) for locally advanced esophageal cancer (LAEC): Results of a phase II trial. (2011) (6)
- O-233 Platinum-based versus non-platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC): A meta-analysis of the published literature (2003) (5)
- Phase I/II study of tumor-infiltrating lymphocyte (TIL) infusion and low-dose interleukin-2 (IL-2) in patients with advanced malignant pleural mesothelioma (MPM). (2015) (5)
- Methodology for clinical trials in cancer patients with febrile neutropenia (1998) (5)
- Pharmacology ofAmikacin inHumans (1974) (5)
- Organization of clinical trials: problems, controversies, definitions, and methodology related to infections in neutropenic patients. (1993) (5)
- Prognostic and predictive effects of TP53 mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC). (2016) (5)
- A clinical and pharmacological study of 5-fluorouracil, leucovorin and interferon alfa in advanced colorectal caner (2004) (5)
- Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a clinical practice guideline (2006) (5)
- Treatment of N2 non-small cell lung cancer (NSCLC). (1989) (5)
- Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients. (2017) (5)
- Canadian multicentre randomized trial comparing two dose levels of thoracic radiation given in combination with chemotherapy to patients with limited small cell lung cancer (1986) (4)
- CEA: A Useful Prognostic Marker in Small Cell Lung Cancer (1985) (4)
- Evolution of the clinical manifestations of infection during the course of febrile neutropenia in patients with malignancy (1998) (4)
- Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma (MPM). (2012) (4)
- Supportive care in patients with cancer: quality of life and ethical issues (1990) (4)
- Squamous cell carcinoma of the bronchus associated with hypercalcemia in a twenty‐year‐old (1981) (4)
- O-201 A phase II trial of induction chemotherapy followed by extrapleural pneumonectomy and high-dose hemithoracic radiation for malignant pleural mesothelioma (2003) (4)
- Quality of life assessment in patients with carcinoma of the lung. (1989) (4)
- Infections and Cancer (2010) (4)
- Referral patterns for adjuvant therapy in non-small cell lung cancer (2005) (4)
- The impact of body mass index on survival in stage 3 and 4 lung cancer. (2013) (4)
- Influence of gender on treatment outcome and toxicity in small cell lung cancer (SCLC) (2004) (4)
- Early side effects of intrathoracic BCG therapy in patients with stage I squamous cell carcinoma, adenocarcinoma, or large cell lung cancer (1981) (4)
- 234 Importance of timing for thoracic irradiation (TI) in the combined modality treatment of limited-stage small-cell lung cancer (LSCLC): An update of the National Cancer Institute of Canada (NCIC) BR6 study (1997) (3)
- Management of Bacterial Infections in Cancer Patients (1976) (3)
- Impact of induction chemotherapy and adjuvant radiation therapy on outcome after extrapleural pneumonectomy for malignant pleural mesothelioma (2007) (3)
- Complications of treatment of small cell carcinoma of the lung. Experience from a recent Canadian trial. (1988) (3)
- Prognostic effect of single versus multiple somatic mutations in non-small cell lung cancer (NSCLC). (2015) (3)
- Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients (2017) (3)
- Phase 1/2 Study of the Addition of Cisplatin to Adjuvant Chemotherapy With Image Guided High-Precision Radiation Therapy for Completely Resected Gastric Cancer. (2016) (3)
- Lung cancer in never-smokers from the Princess Margaret Cancer Centre. (2014) (3)
- Malignant mesothelioma: Canadian perspective and research directions (2008) (3)
- High-dose or dose-intensive chemotherapy for non-small cell carcinoma of the lung. (1994) (3)
- Systemic therapy usage and outcomes for patients diagnosed with malignant pleural mesothelioma (MPM) between 2005 and 2010 in Ontario, Canada. (2011) (3)
- A clinical and pharmacological study of 5-fluorouracil, leucovorin and interferon alfa in advanced colorectal cancer. (1995) (3)
- Accelerated hypofractionated hemithoracic intensity modulated radiation therapy (IMRT) followed by extrapleural pneumonectomy (EPP) for malignant pleural mesothelioma (MPM): Results of a phase I/II study. (2013) (3)
- Chemotherapy versus best supportive care for unresectable non small cell lung cancer: is it really worthwhile? (1993) (3)
- Phase I trial of gemcitabine and cisplatin in advanced non-small cell lung cancer: a preliminary report. (1996) (3)
- Predictive value of coexisting KRAS and TP53 mutations on response to chemotherapy in non-small cell lung cancer (NSCLC). (2015) (2)
- 233 The influence of age on the efficacy and tolerability of combined modality therapy in limited small cell lung cancer (L-SCLC) (1997) (2)
- Varicella-Zoster Infection in Adult Cancer Patients (2017) (2)
- Microbial resistance and the Infectious Diseases Society of America (IDSA) guidelines. (1998) (2)
- O-63 Brain metastases as the initial site of failure in locally advanced non-small cell lung cancer treated with combined modality therapy: Implications for prophylactic cranial irradiation (2003) (2)
- Fourth World Conference on lung cancer August 25–30, 1985 Toronto, Canada (1986) (2)
- The role of supportive care in quality of life. (1996) (2)
- Combined modality therapy in small cell lung cancer. (1994) (2)
- Compliance of adjuvant chemotherapy in non-small cell lung cancer (NSCLC); No longer an issue. (2006) (2)
- Concurrent radiotherapy and chemotherapy in lung cancer at the Princess Margaret Hospital. (1988) (2)
- Retrospective study of the incidence and outcomes from lung cancer in solid organ transplant recipients. (2020) (2)
- PD-101 Review of practice patterns for adjuvant chemotherapy inpatients with completely resected non-small cell lung cancer (NSCLC) (2005) (2)
- A drug interaction study between dextromethorphan and panobinostat (LBH589), an orally active deacetylase inhibitor, in patients with advanced cancer. (2010) (2)
- P-779 Impact of anemia on outcomes of therapy in limited small celllung cancer (L-SCLC): An analysis of studies performed by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) (2005) (2)
- Gefitinib: a consideration of cost (2008) (2)
- Circulating arginine-vasopressin, calcitonin, carcinoembryonic antigen, neuron-specific enolase, and beta-2 microglobulin fluctuations during combined modality induction therapy for small-cell bronchogenic carcinoma. Association of postchemotherapy AVP surge with high tumor response rate and durable (1991) (2)
- Recent advances in the management of infections in cancer patients. (1993) (2)
- Cotrimoxazole-resistant Escherichia coli bacteremia in neutropenic patients at a regional oncology hospital. (1992) (2)
- In Vitro, Pharmacological and Clinical Studies with Amikacin (1976) (2)
- The potential for lost productivity in lung cancer patients. (2006) (2)
- Reply to V. Lorusso et al. (2013) (2)
- Patients with advanced non-small cell lung cancer (NSCLC): Are research biopsies a barrier to participation in clinical trials? (2015) (1)
- Effects of Ethnicity on Outcomes of Patients With EGFR Mutation–Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical Resection (2021) (1)
- 237 What is standard therapy for stage IIIA non-small cell lung cancer (NSCLC)?: A randomized trial of combination chemotherapy (C) and surgery (S) versus radiotherapy (RT) alone (1997) (1)
- Quality of Life in Patients with Febrile Neutropenia (1997) (1)
- Infections in myeloma (1998) (1)
- Treatment Patterns and Outcomes of Patients With Advanced Pleural Mesothelioma at an Academic Referral Centre. (2021) (1)
- ALK‐rearranged non‐small cell lung cancer is associated with a high rate of venous thromboembolism: 176P (2016) (1)
- Economic analysis of TORCH: Erlotinib versus cisplatin and gemcitabine as first-line therapy for advanced non-small cell lung cancer (NSCLC). (2013) (1)
- Complications associated with the treatment of small cell lung cancer. (1994) (1)
- Effect of brain metastases on survival and systemic treatment of EGFR/ALK-driven non-small cell lung cancer (NSCLC). (2016) (1)
- 1480OSYMPTOMATIC TOXICITIES EXPERIENCED DURING ANTI-CANCER TREATMENT: COMPARISON OF PATIENTS' AND PHYSICIANS' REPORTING IN THREE RANDOMIZED CONTROLLED TRIALS (RCTS). (2014) (1)
- Late complications associated with the treatment of small-cell lung cancer. (1989) (1)
- Phase II evaluation of bisantrene in patients with advanced non-small cell lung carcinoma. (1985) (1)
- Late Complications of Therapy of Lung Cancer (1986) (1)
- A phase II study of capecitabine, irinotecan, and bevacizumab (XELIRI-A) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC). (2016) (1)
- Phase II trial of preoperative (POP) irinotecan (I) + cisplatin (C) and radiotherapy for esophageal cancer. (2006) (1)
- 191 Phase II trial of gemcitabine and capecitabine (GemCap) in patients with advanced biliary cancer (2003) (1)
- Carbenicillin plus cephalothin or cefazolin as therapy for infections in neutropenic patients. (1977) (0)
- O-123 Hemithoracic radiotherapy for mesothelioma — challenges and solutions (2003) (0)
- The treatment of inoperable patients with non-small-cell lung cancer. (1994) (0)
- P3.02c-076 Correlation of Neutrophil to Lymphocyte Ratio (NLR) with Clinical Benefit from Checkpoint Inhibitors in Advanced Lung Cancer: Topic: IT Biomarkers (2017) (0)
- A Phase I/Ib study of MEK162 (binimetinib), a MEK inhibitor, in combination with carboplatin and pemetrexed in patients with non-squamous NSCLC. (2016) (0)
- The M ultinational A ssociation f or S upportive C are i n Cancer R isk I ndex: A M ultinational S coring S ystem f or Identifying L ow-Risk F ebrile N eutropenic C ancer P atients (2011) (0)
- O-135IMPACT OF INDUCTION THERAPY ON POSTOPERATIVE OUTCOME AFTER EXTRAPLEURAL PNEUMONECTOMY FOR MALIGNANT PLEURAL MESOTHELIOMA: DOES INDUCTION ACCELERATED HEMITHORACIC RADIATION INCREASE THE SURGICAL RISK? (2015) (0)
- Changes in Body Composition in Patients with Small-Cell Lung Cancer (2020) (0)
- 1578 – PHARMACOLOGICAL AND THERAPEUTIC STUDIES OF SISOMICIN (1977) (0)
- Genetic sequence variant (GSV) in TERT-CLPTM1L (5p15.33 locus) and survival in platinum-treated stage-IV non-small cell lung cancer (NSCLC). (2012) (0)
- The Treatment of Chronic Nausea in Patients with Advanced Cancer (1998) (0)
- Phase I/II study of combined modality therapy in pancreatic cancer with gemcitabine (Gem) and escalating dose radiation therapy (RT) (2001) (0)
- Mesothelin as a marker of response in malignant pleural mesothelioma. (2016) (0)
- P1.06-039 Retrospective Study of the Incidence and Outcomes from Lung Cancer That Developed Following a Solid Organ Transplant: Topic: Advanced General (2017) (0)
- O-118 Optmizing cancer treatment decision-making: Pilot study of a treatment decision aid in stage IV non-small cell lung cancer (2003) (0)
- Empirical Vancomycin in Neutropenic Patients (2019) (0)
- Feasibility and potential benefits of second-line chemotherapy in patients with advanced biliary tract cancer. (2012) (0)
- Studies and lung cancer treatments: impact on survival and quality of life, B.W. Bakker (Ed.). CIP-Data Koninklijke Bibliotheek Den Haag, Leiden, The Netherlands (1986), ISBN: 90-90011323-7 (1987) (0)
- Reduction in clinical response to empiric antimicrobial therapy of febrile granulocytopenic patients receiving TMP/SMX infection prophylaxis. (1992) (0)
- A phase II trial of oblimersen sodium (G3139) in combination with doxorubicin (DOX) in advanced hepatocellular carcinoma (HCC). NCI protocol # 5798. (2006) (0)
- Society News December 2005 (2005) (0)
- P-658 Expression and prognostic significance of c-Kit, PKB/Akt and MAPK in patients with small-cell lung cancer (2003) (0)
- Meropenem V ersus C eftazidime i n t he T reatment o f C ancer Patients W ith F ebrile N eutropenia: A R andomized, Double-Blind T rial (2000) (0)
- 729PIMPACT OF NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) AND PLATELET-TO-LYMPHOCYTE RATIO (PLR) ON OUTCOMES IN HEPATOCELLULAR CARCINOMA (HCC) PATIENTS TREATED WITH SORAFENIB (SOR). (2014) (0)
- P2.03b-008 The Impact of Brain Metastases and Their Treatment on Health Utility Scores in Molecular Subsets of Lung Cancer Patients: Topic: Brain Meta (2017) (0)
- Symposium on the diagnosis and treatment of common cancers. 1. Lung cancer--1983. (1983) (0)
- Lung and mediastinum: Editorial overview (1991) (0)
- Systemic therapy use and outcomes after relapse from accelerated hemithoracic radiation and surgery for malignant pleural mesothelioma (MPM). (2017) (0)
- Developments in fungal infection management (1991) (0)
- 1250PEPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AND ABCG2 POLYMORPHISMS AND TREATMENT OUTCOME IN THE RANDOMIZED PHASE III TORCH TRIAL IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS. (2014) (0)
- Recent advances in supportive care in patients with lung cancer. (1994) (0)
- Optimal thoracic irradiation (TI) in the treatment of limited stage small cell lung cancer (LSCLC) (1991) (0)
- Personalized treatment outcomes in never smokers with advanced non-small cell lung cancer (NSCLC) in the Princess Margaret Cancer Centre. (2015) (0)
- Commentary (Feld): Chemotherapy for Non–Small-Cell Lung Cancer (2003) (0)
- Continuous Infusion of Amikacin Plus Cephalothin (2016) (0)
- Anemia rates in completely resected non-small cell lung cancer (NSCLC) patients receiving adjuvant chemotherapy; An interim analysis: P1-249 (2007) (0)
- Meropenem Versus Cef taz id ime in the Treatment of Cancer (2000) (0)
- EGFR mutations in NSCLC: Does ethnicity influence outcomes? (2015) (0)
- 1249PCMET EXPRESSION AND ACTIVITY OF FIRST-LINE ERLOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS): EXPLORATORY ANALYSIS OF THE RANDOMIZED PHASE III TORCH TRIAL. (2014) (0)
- Real-world EQ5D health utility values for metastatic lung cancer patients by molecular alteration and response to therapy. (2016) (0)
- Single nucleotide polymorphisms (SNPs) of the platinum pharmacogenetic and VEGF pathways: Association with survival of platinum-treated stage IV non-small cell lung cancer (NSCLC) patients. (2012) (0)
- Multicentre Canadian clinical trials on neutropenic patients. (1992) (0)
- Sisomicin alone and in combination for infections in cancer patients (1979) (0)
- P-507 Randomized trial to investigate the impact of a computer-generated quality of Life assessment program on treatment patterns for advanced non-small cell lung cancer patients (2005) (0)
- DPD defi ciency in patients treated with fl uorouracil (2015) (0)
- Response to letter 'outcome of second-line chemotherapy for biliary tract cancer'. (2013) (0)
- Expression and Prognostic Significance of Kit , Protein Kinase B , and Mitogen-activated Protein Kinase in Patients with Small Cell Lung Cancer 1 (2003) (0)
- Current perspectoves in the treatment of non-small cell lung cancer (1993) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Ronald Feld?
Ronald Feld is affiliated with the following schools:
